ArticleBritish journal of haematology2019

Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.

Huijuan Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.